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N-acetyl aspartate (NAA) is a marker of disability in secondary progressive multiple 
sclerosis: a proton magnetic resonance spectroscopic imaging study  
Abstract  
Background and Purpose: 
We undertook a 1H-MRS imaging study in a large secondary progressive MS (SPMS) cohort, 
to examine whether metabolic markers of brain injury are associated with measures of 
disability.  
Methods: 
A cross-sectional analysis of people with SPMS was performed in 119 participants. They 
underwent 1H-MRS to obtain estimated concentrations and ratios to total Cr for total NAA, 
mIns, Glx and total Cho in normal appearing WM (NAWM) and GM. Clinical outcome 
measures chosen were: Paced auditory serial addition test (PASAT3), Symbol digit modalities 
test, nine-hole peg test (9HPT), Timed 25-foot walk and Expanded Disability Status Scale. The 
relationship between these neurometabolites and clinical disability measures was initially 
examined using Spearman rank correlations. Significant associations were then further 
analysed in multiple regression models adjusting for age, gender, disease duration, T2 lesion 
load, normalised brain volume and occurrence of relapses in two years preceding study entry.  
Results: 
Significant associations which were then confirmed by multiple linear regression were found 
in NAWM for: tNAA/tCr and 9HPT [Rho=0.23, 95% CI [0.06-0.40]; tNAA and tNAA/tCr and 
PASAT3 [Rho=0.21, 95% CI [0.03-0.38], [Rho=0.19, 95% CI [0.01-0.36]; mIns/tCr and 
PASAT3 [Rho= -0.23, 95% CI [-0.39 -to -0.05]; and in GM for tCho and PASAT3 [Rho=-
0.24, 95% CI [-0.40 to -0.06]. No other GM or NAWM relationships were found with any 
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metabolite, with associations found during initial correlation testing losing significance after 
multiple linear regression analysis. 
 
Conclusion: 
This study suggests that metabolic markers of neuroaxonal integrity and astrogliosis in 


















9HPT Nine-hole peg test 
CSI Chemical shift imaging 
EDSS Expanded disability status scale 
IPS Information processing speed 
NAWM Normal appearing white matter 
PASAT3 Paced auditory serial addition task (3 second) 
SDMT Symbol digit modalities test 
SPMS Secondary progressive multiple sclerosis 
T25FW Timed 25-foot walk  
WML White matter lesion 
 
INTRODUCTION 
Secondary progressive multiple sclerosis (SPMS) is the dominant progressive form of multiple 
sclerosis that is characterised by accumulating disability due to a variety of neurodegenerative 
processes.1 These include microglial activation with subsequent formation of reactive oxygen 
species inducing mitochondrial damage; sodium channel dysfunction leading to histotoxic 
hypoxia and axonal energy failure; and glutaminergic excitotoxicity.2–4  
Surrogate markers of brain injury are valuable in improving our understanding of the 
pathophysiology driving clinical disability in progressive MS. Surrogate imaging-based 
markers such as MRI based lesional and atrophy metrics, can identify existing inflammatory 
injury and axonal loss and provide adjunctive prognostic information. Yet existing imaging 
based-measures are relatively limited in their ability to demonstrate metabolic or 
microstructural changes and show only a modest association with clinical disability outcomes 
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in progressive MS (PMS).5 This is where advanced non-structural MRI techniques such as 1H-
MRS are attractive to further understand this neuropathology and its association with clinical 
disability in progressive forms of MS.  
Using 1H-MRS, neurometabolites of interest in MS include: N-acetyl aspartate plus N-acetyl 
aspartyl glutamate (total NAA = tNAA), a marker of neuroaxonal integrity and mitochondrial 
function;6,7 Glx – the sum of the excitatory neurotransmitter glutamate and its precursor 
glutamine;4 myo-inositol (mIns), a marker of glial cell activity, most likely astrogliosis; and 
total Choline (tCho = glycerophosphocholine and phosphocholine) – a marker of membrane 
turnover.7,8 Many studies have demonstrated decreases in tNAA and tNAA/tCr; and increases 
in total creatine (tCr = creatine and phosphocreatine) and inositol in normal appearing white 
matter (NAWM) and GM in SPMS.9 In a recent meta-analysis of 1H-MRS studies, effect sizes 
for a reduction in NAA and NAA/Cr were larger in PMS compared to relapsing-remitting MS.9 
There have been conflicting results from studies examining disability associations in PMS: 
several studies showed no association between metabolites (NAA, Glx, mIns, tCho) and the 
Expanded disability status scale (EDSS);10–13 whilst others showed moderate associations with 
EDSS, nine-hole peg test (9HPT), Timed 25 foot walk test (T25FW) in cortical GM and 
NAWM.14–16 Of the studies examining cognitive performance [including information 
processing speed (IPS)] in PMS, no associations were found in sample sizes ranging from 14-
31, with only two of these studies containing pure SPMS cohorts.13,14,16–18  
The rationale for this cross-sectional study was to further define metabolite levels, and their 
associations with disability, in a much larger sample of people with SPMS than has been 
achieved before.  
Methods: 
Participants and measures 
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Participants were recruited from the MS- Secondary Progressive Multi-Arm Randomisation 
Trial (MS-SMART) (NCT01910259) – a phase 2b double-blind, placebo-controlled, multi-
arm, multi-centre study assessing the neuroprotective potential of amiloride, fluoxetine and 
riluzole in SPMS. Details of the trial protocol and final trial results were recently published.19,20 
Participants recruited into the study were people with SPMS aged 25-65 with an EDSS score 
of 4.0-6.5, that showed evidence of progression independent of relapses over the last 2 years. 
Participants were randomised 1:1:1:1 to amiloride, fluoxetine, riluzole or placebo, and the 
primary outcome measure was the percentage brain volume change over 96 weeks. 
Participants involved in the MS-SMART study at our site (Queen Square MS Centre, 
University College London) were invited to take part in an optional “Advanced MRI sub-
study” inclusive of 1H-MRS scans. Recruited participants had their MRI scan and clinical 
assessments prior to randomisation and commencing study medication. They underwent a 
series of clinical assessments including EDSS, T25FW, 9HPT and two standard measures of 
IPS: Paced Auditory Serial Addition Test-3 (PASAT3) and Symbol Digit Modalities Test 
(SDMT).21–23  MRI measures included normalised brain volume, normal appearing WM 
(NAWM), cortical GM and T2 lesion volume.  
Consent was obtained for all participants according to the Declaration of Helsinki and ethical 
approval for the study was provided by the Scotland A Research Ethics Committee 
[13/SS/0007]. 
MRI acquisition 
Neurometabolite spectra from multiple voxels within one scan were acquired using a technique 
known as chemical shift imaging (CSI) to determine estimated neurometabolite concentrations 
and ratios by obtaining average metabolite concentrations from a slice of neuronal tissue.24 
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Imaging was acquired using a Philips Achieva 3T MRI scanner (Philips Healthcare, Best) using 
a 16ch neurovascular coil. 
All participants underwent the following scans:  
MRS: A 210x160mm2 VOI with 15mm slice thickness was selected for CSI, placed superior 
to the lateral ventricles (Fig. 1). The inferior margin of the slice was positioned at the superior 
margin of the corpus callosum, angulated to the anterior commissure/ posterior commissure 
line. At the baseline visit, a screen shot of the exact positioning of the CSI was saved (see Fig. 
1) to be used as a reference for subsequent time points. The slice placement was chosen to 
avoid the ventricles to ensure that all voxels were of consistent quality and shim.  The CSI VOI 
was subdivided into a 21x16 grid giving a voxel size of 10x10x15mm3. Spectra were acquired 
using the manufacturer’s 2D Point RESolved Spectroscopy sequence (short TE 35ms/ TR 
2000ms). Outer volume suppression using fat saturation was applied to limit artefacts, and the 
VOI was shimmed using the pencil beam-auto technique.25 CHEmical Shift Selective 
saturation  pulses were used for water suppression.  A reference scan with no water suppression 
was also collected with identical parameters during the same exam for quantification. tNAA 
(total NAA = N-acetyl aspartate and N-acetyl aspartyl glutamate), mIns, Glx (sum of glutamate 
and glutamine), tCho (total choline = glycerophosphocholine and phosphocholine) and each of 
their ratios to total creatine (sum of creatine and phosphocreatine) were calculated. 
Structural MR imaging: Scans for structural information and lesion assessment were 
collected prior to MRS as detailed below and were used also for planning purposes. A sagittal 
3D-T1WI with matrix 256 x 256, FOV 256 x 256mm2, 180 sagittal slices 1mm thick, flip angle 
8o, TR/TI/TE = 7/840/3.2 ms (turbo factor 230) was acquired for structural information. An 
axial PD-T2 (TR/TE1/TE2) = 3500/19/85 ms, turbo factor 10) and FLAIR (TR/TI/TE = 
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8000/2400/125 ms, turbo factor 24) with matrix 240 x 180, FOV 240 x 180 mm2, 50 slices 
3mm thick were acquired for lesion assessment.  
MRI analysis 
Brain and WM lesion segmentation 
In order to obtain segmentations of WM, GM and CSF, a NIFTI image was created in the same 
space as the axial PD-T2 to represent the positioning of the CSI matrix and to act as a mask for 
the MRS volume (Fig. 1). The axial PD-T2 image was rigidly registered and resampled to the 
3D T1 image space using NiftyReg,26 and an identical transform applied to the CSI mask to 
get the matrix in the desired space for segmentation. WM lesions were semi-manually 
delineated using Jim 7 (Xinapse Systems) on the T2WI using the FLAIR image as a reference. 
After lesion filling,27 the 3D-T1WI was segmented using geodesical information flows 
enabling the calculation of T2 lesion volume.28 
Brain volume measures 
Normalised brain volume was calculated using the SIENAX method from the segmented 3D-
T1WI.29 SIENAX rescales each subject head to an Montreal Neurological Institute atlas size, 
hence correcting each individual brain volume. Thus, the normalised brain volume is the 
volume of the rescaled brain and it allows us to correct brain volume for variations in head size, 
effectively resulting in a measure of cross-sectional atrophy.29 
CSI Spectra & image post-processing: 
Following the acquisition, post-processing of spectra was completed using Linear Combination 
of Model Spectra (LCModel© version 6.3-1A) – a program used to fit MRS data to a basis set, 
which together with the water reference scan, enabled estimated quantification of metabolites 
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as well as providing a set of parameters to perform quality assurance for each voxel.30 The 
LCModel basis set was provided by S. Provencher (personal communication). 
The water reference scan was used to find a scaling factor for the basis set, as detailed in the 
LCmodel manual.30 This carries with it the assumption that the concentration of water in the 
spectrum is equivalent to healthy white matter (35880mM), which, in the absence of a specific 
measure per patient is often used as the default.30,31 In addition to this to correct for T2 
relaxation the default water attenuation was set to 0.7, based on TE=30 and on Ernst et al. who 
found the major water compartment in brain has T2 ≈ 80 ms. (exp(−TE/T2) = exp (−30/80) ≈ 
0.7).30,31 If substituted for TE=35ms this reduces to 0.65, however in the absence of an accurate 
T2 in pathology, the default was again kept (Sec 11.2 LCmodel manual). As we employed long 
TR and water scaling was used, no correction for T1 was made.  
Spectra from individual voxels were automatically rejected if any neurometabolite Cramer-
Rao lower bounds were > 20%, full width half-maximum of the tNAA spectral peak was >15Hz 
or SNR < 9. All voxels that passed the automated step were visually inspected by an 
experienced assessor (BS) to look for baseline artefacts, non-random residuals or outer volume 
contamination that may prevent the accurate measurement of neurometabolites. The resulting 
set of voxels made up a “clean data” set which all passed the automated and visual QA. 
Figure 2. An example spectrum from a single voxel of brain tissue and spectra from the 
chemical shift imaging grid  
 
Neurometabolite analysis:  
Neurometabolites were analysed in the following two ways: 
i. Estimated metabolite concentrations: The mean metabolite concentrations (tNAA, 
mIns, Glx, tCho) of all voxels which passed the automatic and visual quality assurance 
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(clean data) were averaged for each participant to calculate per patient estimated 
metabolite concentration reported in institutional units (i.u.).  
ii. Metabolite ratios: Mean neurometabolite ratios (tNAA, mIns, Glx, tCho) to total 
creatine (tCr) were calculated from the clean data for each participant.  
Metabolite concentrations and ratios were then calculated in the following two tissue types:  
i) Normal appearing white matter (NAWM) 
ii) Grey matter (GM) 
To eliminate contamination by WML and CSF, we firstly removed any voxels containing > 
1% WML and > 15% CSF. Linear regression models were used to explore the association 
between the concentration of each metabolite and white or grey matter fraction on a voxel by 
voxel basis. These models were then extrapolated to find the value for each metabolite where 
GM or WM fraction was 100% to find the metabolite concentration for each tissue type. 
Metabolite outliers were removed from the regression models leaving us with per patient 
metabolite values. This method has been previously described.32 Owing to the small lesion load 
in the acquired slice (average WML fraction in SPMS cohort was 0.01), calculation of 
metabolite values in WML was unable to be completed. 
Statistical analyses 
Neurometabolic data and distribution over the cohort was summarised descriptively. Statistical 
analysis was completed using R statistical software (version 3.5.1).33 All p values were two 
tailed and reported using a 0.05 significance level.  
Neurometabolite correlations with clinical disability measures: 
To examine the association between tissue specific neurometabolites and clinical disability 
measures (EDSS, T25FW, 9HPT, PASAT3, SDMT), Spearman rank correlation coefficients 
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were calculated given the non-normal distribution of the clinical disability measures. The scope 
of the analysis was to analyse the association between our key metabolites in NAWM and GM 
(tNAA, mIns, Glx, tCho and their ratios to tCr) and the disability measures listed above. During 
correlation testing, sixty comparisons were pre-specified but here we report eighty after tCho 
(and tCho/tCr) were added following a post-hoc request by a peer reviewer. These are reported 
in Table 3. In reporting multiple analyses, we were guided by considerations outlined in Patel 
C et al.: multiplicity adjustment is not required when  a list of hypotheses of primary importance 
are pre-specified; emphasis is placed on being explicit and transparent about the extent of 
multiplicity; and the magnitude of observed associations is interpreted in the context of the 
background literature.34    
Where statistically significant correlations were found in the Spearman rank correlation 
analysis, a subsequent multivariable linear regression analysis was performed, adjusting for 
age, gender, disease-duration from onset, occurrence of relapses in the preceding two years, T2 
lesion volume and normalised brain volume. Model diagnostics undertaken to assess the 
regression model included: calculation of variance inflation factors to determine multi-
collinearity; Cook’s distance to determine effect of leveraged data points; plots of studentised 
residuals against adjusted predicted values to check residual homoscedasticity.  
Results: 
154 participants gave consent for the Advanced MRI sub-study from January 2015 to June 
2016. Of these 154 participants, six failed the CSI quality assurance leaving 148 participants 
in the CSI arm of the Advanced MRI sub-study at baseline. 
In total there were 8361 CSI voxels for the analysis which passed both automatic and visual 
quality assurance. 3035 voxels remained after excluding voxels that contained > 1% WML and 
> 15% CSF (mean 20.5 voxels per patient, standard deviation 9.2). After calculating metabolite 
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values and removing metabolic outliers, 119 SPMS participants remained for analysis. Cohort 
demographics are provided for the cohort of 119 participants that underwent correlation testing 
and regression analysis. 81/119 (68%) were female and 108/119 (91%) had not experienced a 
relapse in the two years before randomisation. Further details of the cohort are shown in table 
1.  
Table 1. Cohort demographics and characteristics 
 
Estimated neurometabolite concentrations (in i.u.) and metabolite ratios to tCr can be found in 
Table 2.  
 
Table 2. Summary statistics for neurometabolite estimated concentrations (i.u) and 
ratio to total creatine 
 
Metabolite concentrations/ratios which showed statistically significant correlations to 
disability measures in NAWM and GM are shown in Table 3.  
 
Table 3. Correlations between neurometabolites and clinical disability measures 
 
Table 4 shows the results of the regression analysis for neurometabolites that were significantly 
associated with clinical disability measures after adjusting for covariates. Neurometabolites 
that showed a statistically significant association on the Spearman rank correlation but lost 
statistical significance after regression analysis are not shown in table 4. In NAWM, 
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associations were seen between tNAA/tCr and 9HPT (β = 0.23, p = 0.04); tNAA and tNAA/tCr 
and PASAT3 (β = 0.17, p = 0.04), (β = 0.19, p = 0.02) respectively; and mIns/tCr and PASAT3 
(β = -0.22, p = 0.007). In GM, tCho was associated with PASAT3 (β = -0.27, p = 0.04). 
 
Table 4. Statistically significant associations between neurometabolites and clinical 
disability measures from regression analysis 
 
Figure 3. Associations between neurometabolites and clinical disability measures 
 
Discussion: 
This is the largest reported cohort of people with SPMS undergoing 1H-MRS. Table 3 shows 
all of the correlations with those in bold as statistically significant. They were then explored in 
a multiple regression analysis (table 4). The results suggest a relationship in NAWM between 
tNAA (tNAA/tCr) and mIns/tCr and IPS performance (PASAT3); and between tNAA/tCr and 
upper limb function (9HPT). In GM, tCho was associated with IPS performance. Whilst a 
number of other correlations were identified in the correlation analysis, no associations with 
EDSS or T25FW were found in GM or NAWM after multiple regression analysis.  
 
Relationships between neurometabolites and clinical disability (refer table 4): 
 
Upper limb function 
Previous smaller studies examining tNAA or tNAA/tCr in NAWM in PMS have not 
demonstrated statistically significant associations between neuroaxonal integrity and upper 
limb function.14,16  Our study suggests that as neuroaxonal integrity (and mitochondrial 
function) decreases, upper limb function, as reflected by 9HPT, also decreases. The association 
found between tNAA/tCr and 9HPT during the correlation analysis (see table 3) and multiple 
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regression head in the expected direction with decreased tNAA/tCr associated with decreased 
upper limb function (as reflected by 9HPT). It remains of interest whether this is reflective of 
regional changes in NAWM that affect specific tracts related to upper limb and hand function 
or are the changes more reflective of generalised changes throughout the NAWM. With the 
association being seen with 9HPT but not T25FW, it may suggest that changes in neuroaxonal 
integrity and mitochondrial function in the brain play a more significant role in upper limb 
dysfunction in the progressive stage of the disease. This could be further explained by the 
hypothesis that PMS is a length dependent central axonopathy whereby legs are affected earlier 
due to greater susceptibility of spinal cord motor neurons; and the greater reserve capacity of 
shorter neuronal pathways such as the upper limb earlier in progressive disease.35 Sastre-
Garriga et al found an association between tNAA and 9HPT in cortical GM (r = -0.48, p = 
0.03) and in this context the correlation in this study of 0.22 (see table 3) is lower – although 
our association was in NAWM rather than cortical GM.14 Our result contrasts with previous 
studies but this could be explained by the differences in cohort characteristics whereby Sastre-
Garriga et al examined 43 predominantly male participants with early PPMS with a lower 
median EDSS of 4.5 and Obert et al analysed 15 SPMS with a median EDSS 4.5.14,16  
Information processing speed: 
A previous much smaller study examining measures of IPS (PASAT3) and its relationship to 
in vivo neurometabolites in NAWM in SPMS (n = 15) did not show any associations.16 Several 
other studies reported results in the form of standardised scores such as MS Functional 
composite or the Brief Repeatable battery, making it difficult to discern the true relationship 
between IPS and neurometabolites in PMS.13,14,18 Firstly, our findings of an association 
between NAWM tNAA and tNAA/tCr with PASAT3 scores (see table 3 & 4, figure 3) are in 
the expected direction, with decreased neuroaxonal integrity in NAWM, associated with 
decreased performance on the PASAT3. We are unable to determine whether there was a 
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predilection to a specific region of NAWM or whether it was possibly associated with altered 
functional or structural connectivity. Solana et al examined this in a mixed cohort of relapsing 
remitting MS and SPMS, demonstrating that NAA/Cr and mIns/Cr in WM were associated 
with abnormal efficiency in the front-parietal network with abnormalities in this network 
associated with impaired attention and processing speed (compared to healthy controls).32  Our 
findings differed from Obert et al who employed a similar 1H-MRS acquisition to calculate 
NAA/Cr, but their SPMS cohort of 14 undergoing 1H-MRS may not have had sufficient power 
to detect an association.  Gender is also associated with IPS with females being associated with 
decreased PASAT3 scores compared to males adjusting for the other covariates (see Table 4). 
Neurometabolic differences between males and females in SPMS was examined by De Stefano 
et al. who did not find differences in NAA/Cr in NAWM.36 There was also no difference in 
tNAA or tNAA/tCr in NAWM between males and females in our SPMS cohort (welch t test: 
p = 0.3, p = 0.7 respectively). Penny et al examined the longitudinal association between NAA 
and IPS in PMS and did not identify gender as being associated with 5-year measures of IPS. 
Their results however may differ as they studied a cohort of PPMS that had a predominance of 
males and a lower baseline median EDSS of 4.5.37 T2 lesion volume reflecting the 
inflammatory lesion burden was also associated with IPS and cognitive performance– findings 
that have been demonstrated before confirming the strong association between inflammatory 
lesion burden and clinical disability in PMS.18,37  
We also found that mIns/tCr in NAWM had a negative association with PASAT3 scores (see 
Table 3 & 4). This relationship is in the expected direction with increased astrogliosis (as 
reflected by higher mIns/tCr) associated with decreased performance on PASAT3.  mIns values 
were not associated with tests of IPS but the ratio between the two showed a weak negative 
association which suggests that as mIns/tCr ratio increases, PASAT3 scores decrease (see 
figure 3). This finding could be driven by either an increased mIns or decreased tCr (tCr is 
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more commonly used a reference metabolite) and reflective of increased astrogliosis in SPMS, 
causing IPS dysfunction.  
There was a correlation between tNAA in NAWM and SDMT.  However, this association was 
not significant after adjusting for covariates in the regression analysis. Whilst both PASAT3 
and SDMT measure IPS, PASAT3 involves verbal work memory compared to SDMT which 
involves visuo-spatial memory and this may explain the association between neuroaxonal 
integrity in NAWM and PASAT3 but not SDMT.38 A separate study comparing PASAT to 
SDMT using fMRI found that PASAT activated more frontal areas and the left inferior parietal 
lobe, suggesting that PASAT required more working memory capacity and executive function 
to execute compared to SDMT.39  However, studies in RRMS suggest strong correlation 
between PASAT3 and SDMT and with similar sensitivity and specificity between the two tests, 
so our lack of association with SDMT should be interpreted with caution.40   
A previous study of choline levels in cortical GM did not show any difference between primary 
progressive MS and healthy controls; nor was there any association with clinical disability 
measures.14 Our results suggest an association between GM tCho (a surrogate marker of 
membrane turnover) and IPS - as GM tCho levels increase, IPS performance (reflected by 
PASAT3 scores) decreases (see Tables 3 and 4, figure 3). Phosphatidylcholine is one of the 
major choline containing compounds contained within cell membranes and there is evidence 
that this along with its precursor molecule phosphocholine and breakdown product 
glycerophosphocholine are measured by the tCho peak in 1H-MRS.41 Along with this, the 
consistent finding of increased tCho (tCho/tCr) in active MS lesions suggests that tCho is a 
marker of membrane turnover.9 Recent findings have demonstrated that meningeal lymphoid 
follicles release pro-inflammatory molecules that can lead to cortical GM inflammation in 
SPMS and our findings may support this with a surrogate marker of increased membrane 
turnover in cortical GM being associated with IPS.42,43 However, this should be interpreted 
16 
 
with caution because tCho was not associated with other measures of clinical disability. Our 
findings may have differed from the previous study as Sastre-Garriga et al examined a cohort 
of 41 participants with early PPMS and lower disability (median EDSS 4.5, mean disease 
duration 3.31 years).14  
Previous studies exploring the relationship between brain neurometabolites and measures of 
IPS in PMS did not report the correlation coefficients making it difficult to place our results in 
the context of previously reported results.14,16,18,44 Though, examining the associations in these 
studies between metabolites and other clinical disability measures e.g. EDSS would suggest 
that the size of our correlations (see table 3) are not out of keeping with previously reported 
work.14,16   
Although there were statistically significant correlations in GM between mIns and PASAT3 
scores, mIns/tCr and SDMT scores and mIns/tCr and T25FW (see table 3), these were not 
significant in the regression analysis adjusting for other covariates and is generally in keeping 
with previous studies that have examined associations between cortical GM metabolites and 
clinical disability measures such as EDSS and the Brief repeatable battery in SPMS 
cohorts.13,45–47 A single study found tNAA was decreased in cortical GM compared to controls 
and tNAA in cortical GM showed a moderate association with EDSS and 9HPT but this was 
in early PPMS.14 When calculating GM metabolites, several studies used careful placement of 
the VOI using single voxel spectroscopy;13,46 whilst the remaining studies used CSI followed 
by automated or manual tissue segmentation.45,47 These differing techniques reflect the 
technical challenges in GM metabolite calculation where the partial volume effect can result in 
contamination of the VOI or leaving insufficient pure GM voxels. The other issue is that 
previous studies have reported clinical measures that reflect general disability or composite 
scores e.g. EDSS and Brief repeatable battery, making it difficult to determine associations 
with specific functional measures such as upper limb function or ambulation. We attempted to 
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address these issues using CSI followed by segmentation; then using a regression method to 
calculate GM metabolite values, and then examining these associations with specific functional 
measures of clinical disability.  
Measures of ambulation and general disability: 
Whilst there were several associations seen between metabolites and T25W and EDSS (see 
table 3), after multiple regression analysis we did not find any significant associations between 
the T25FW performance or the EDSS and any neurometabolite levels. Previous studies 
examining SPMS cohorts have shown relationships between total choline and EDSS in 
NAWM; and tNAA/Cr in cortical GM and EDSS in a cohort of PPMS (n=15).16 The lack of 
association between metabolites and EDSS could be due to the limited distribution of  scores 
in the cohort where 106/148 had an EDSS score of 6.0-6.5; compounded by the ceiling effect 
and non-linear characteristics of the EDSS.35 EDSS particularly between 4.0-6.5 is defined by 
ambulatory distance and there is a moderate to strong correlation between the T25FW and 
EDSS.48 Or there is no relationship to be found. 
There were statistically significant correlations between GM Glx (Glx/tCr) and EDSS; and with 
T25TW (see table 3) but after multiple regression analysis, we did not find any significant 
relationships between Glx or Glx/tCr and measures of clinical disability. Glutaminergic 
excitotoxicity has been shown to be involved in the pathogenesis of progressive MS.4 When 
glutamate values were measured separately to glutamine using a TE averaged MRSI technique, 
glutamate was associated with a decline in neuroaxonal integrity in a mixed cohort of MS 
(number of PMS = 31/343).49   We measured Glx (glutamine + glutamate) due to the difficulty 
in resolving glutamate from its precursor glutamine at 3T. It also seems unlikely that we can 
measure glutaminergic excitotoxicity directly as the majority of Glx signal arises from the 
intracellular compartment and thereby is more likely to reflect neuro-axonal integrity.   
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Methodological and analytical considerations 
The demographics and characteristics (n=119) of the cohort analysed in this study were 
consistent with those reported from the main MS-SMART study (n=445).20 The placement of 
the CSI grid above the ventricles was designed to limit the effect of ventricles from which there 
is no metabolite signal, decrease partial volume effect and ensure consistency of shimming 
across the CSI slice. The predilection of WML to periventricular regions led to voxels 
containing predominantly WM and GM and meant we were unable to obtain metabolite values 
from WML. When determining metabolite values for NAWM and GM, we attempted to limit 
contamination by WML and CSF by excluding voxels that contained 1% WML and 15% CSF. 
These parameters kept the best balance between the loss of CSI voxels whilst minimising WML 
and CSF contamination of voxels used in NAWM and GM calculations. During the calculation 
of metabolite values in NAWM and GM, 29 participants were excluded as metabolite outliers. 
No formal statistical comparison was undertaken but the characteristics of these 29 participants 
were generally similar to those in the cohort that underwent analysis (n=119), except to note 
the median T2 lesion volume was higher in the excluded group (15.6mL v 9.7mL). While we 
outline a rationale for dealing with multiple comparisons, some caution is advised during 
interpretation of the associations due to the multiple comparisons being undertaken. Owing to 
technical difficulties in GM lesions detection, GM lesions were not segmented and this should 
be acknowledged when interpreting metabolite values and results pertaining to GM.  
The neurometabolite ratios to tCr need careful interpretation as tCr is also affected by 
neuropathology.11 There are however benefits to using tCr as a stable reference as it removes 
the need to adjust for head coil loading, T1 and T2 effects.9 Estimated concentrations are 
reported using water reference for scaling which can be used to produce absolute 
concentrations; this in turn carries assumptions within LCModel about the water content of 
tissue, which is based on reports from normal healthy volunteers,50 given this assumption and 
19 
 
the fact that at TR=2000ms T1 effects may still be present, we chose to present an estimated 
(rather than absolute) concentration in institutional units.  The use of estimated concentrations 
allows for the fact that errors between the LCmodel “absolute” concentrations and the true 
metabolite concentrations may be present. 
In summary, after multiple regression analysis tNAA, tNAA/tCr and mIns/tCr in NAWM and 
tCho in GM are associated with clinical disability in upper limb function and information 
processing speed. These metabolites are therefore of interest as surrogate markers of brain 
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Table 1: Baseline demographics and characteristics (n=119) 
Clinical Variable Mean (standard deviation) 
Age (years) 54.2 (6.7) 
EDSS+ 6.0 (4.0-6.5) 
Normalised brain volume (mL) 1418 (87.3) 
Nine-hole peg test (sec-1)* 0.035 (0.01) 
SPMS duration (years) 22.3 (9.2) 
PASAT3 Score (out of 60) 43.0 (11.5) 
SDMT Score (out of 110) 46.9 (11.0) 
T2 lesion volume+ (mL) 9.7 (0.3-34.6) 
T25FW (sec) 10.6 (4.3-180.0) 
+ = median (range), EDSS = Expanded disability status scale, PASAT3 = Paced auditory serial 
addition task, SDMT = symbol digit modalities test, SPMS = Secondary progressive multiple 
sclerosis, T25FW = Timed 25-foot walk test 
*Nine-hole peg test calculated by taking the reciprocal of the average of two trials for each arm 










Table 2 (supplementary appendix):  
Summary statistics for neurometabolite estimated concentrations (in institutional units) and 
ratios to total creatine (n = 119) 
Neurometabolite Mean SD Median Max Min 
NAWM tNAA 8.09 1.04 8.05 10.56 5.62 
NAWM tNAA/tCr 1.34 0.14 1.34 1.82 1.08 
NAWM mIns 4.72 0.91 4.68 7.03 2.75 
NAWM mIns/tCr 0.79 0.13 0.78 1.14 0.52 
NAWM Glx 10.01 1.62 9.96 14.23 6.28 
NAWM Glx/tCr 1.68 0.23 1.69 2.75 1.07 
NAWM tCho 1.46 0.26 1.44 2.19 0.70 
NAWM tCho/tCr 0.24 0.03 0.24 0.32 0.17 
GM tNAA 9.49 1.96 9.73 13.85 4.21 
GM tNAA/tCr 1.36 0.23 1.35 1.88 0.75 
GM mIns 5.11 1.41 5.05 8.68 1.60 
GM mIns/tCr 0.73 0.21 0.72 1.43 0.19 
GM Glx 12.22 3.44 11.91 20.02 5.54 
GM Glx/tCr 1.75 0.45 1.77 3.05 0.79 
GM tCho 1.60 0.39 1.63 2.34 0.37 
GM tCho/tCr 0.23 0.06 0.23 0.39 0.02 
 
Glx = glutamate and glutamine, GM = grey matter, mIns = myoinositol, NAWM = normal 
appearing white matter, SD = standard deviation, tCho = glycerophosphocholine and 




Table 3. Spearman Rank correlations between neurometabolites (Estimated concentrations and ratios) and disability measures (n = 119).   
 EDSS Timed 25 foot walk Nine-hole peg test PASAT3 scores SDMT Scores 
 Rho 95% CI Rho 95% CI Rho 95% CI Rho 95% CI Rho 95% CI 
NAWM tNAA 0.10 -0.08 0.28 0.07 -0.11 0.25 0.22* 0.05 0.39 0.21* 0.03 0.38 0.20* 0.02 0.37 
NAWM tNAA/tCr 0.02 -0.17 0.19 -0.05 -0.23 0.13 0.23* 0.06 0.40 0.19* 0.01 0.36 0.14 -0.05 0.31 
NAWM mIns -0.11 -0.29 0.07 -0.06 -0.24 0.12 -0.01 -0.19 0.17 -0.15 -0.32 0.03 0.00 -0.18 0.18 
NAWM mIns/tCr -0.26** -0.42 -0.09 -0.20* -0.37 -0.03 -0.03 -0.21 0.15 -0.23* -0.39 -0.05 -0.08 -0.26 0.10 
NAWM Glx 0.08 -0.10 0.26 0.10 -0.08 0.28 0.00 -0.18 0.18 0.00 -0.18 0.18 0.19* 0.01 0.36 
NAWM Glx/tCr 0.03 -0.15 0.21 0.07 -0.11 0.25 -0.12 -0.29 0.07 -0.12 -0.30 0.06 0.04 -0.15 0.22 
NAWM tCho -0.10 -0.27 0.08 0.00 -0.18 0.18 0.09 -0.09 0.26 0.17 -0.01 0.34 0.17 -0.01 0.34 
NAWM tCho/tCr -0.22 -0.39 -0.04 -0.12 -0.30 0.06 0.05 -0.14 0.22 0.12 -0.06 0.29 0.07 -0.12 0.24 
GM tNAA -0.16 -0.33 0.02 -0.14 -0.31 0.04 0.05 -0.13 0.22 0.02 -0.16 0.20 0.08 -0.10 0.26 
GM tNAA/tCr -0.05 -0.23 0.13 -0.01 -0.19 0.17 0.08 -0.11 0.25 0.05 -0.13 0.23 0.06 -0.12 0.24 
GM mIns 0.10 -0.08 0.28 0.18 0.00 0.34 -0.14 -0.32 0.04 -0.20* -0.37 -0.02 -0.10 -0.27 0.09 
GM mIns/tCr 0.18 0.00 0.35 0.28** 0.10 0.44 -0.15 -0.32 0.03 -0.14 -0.32 0.04 -0.18* -0.35 0.00 
GM Glx -0.28** -0.44 -0.10 -0.30*** -0.45 -0.13 0.04 -0.14 0.22 0.14 -0.04 0.31 0.03 -0.15 0.21 
GM Glx/tCr -0.22* -0.39 -0.04 -0.26*** -0.42 -0.08 0.06 -0.12 0.24 0.19 0.01 0.36 -0.02 -0.20 0.17 
GM tCho 0.11 -0.07 0.28 0.11 -0.07 0.29 -0.05 -0.23 0.13 -0.24** -0.40 -0.06 -0.08 -0.25 0.11 




Statistically significant correlation coefficients are highlighted in bold text. p < .001 ***, p < .01 **, p < .05 *   
EDSS = Expanded disability status scale, GM = grey matter, Glx = glutamate and glutamine, mIns = myoinositol, NAWM = normal appearing 
white matter, PASAT3 = Paced auditory serial addition task, SDMT = symbol digit modalities test, tCho = glycerophosphocholine and 
phosphocholine, tCr = creatine and phosphocreatine, tNAA = N-acetyl aspartate and N-acetyl aspartyl glutamate
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Table 4: Results from multiple regression analysis examining associations between 
neurometabolites and clinical disability measures 
Nine-hole peg test*** (n = 118) 
Predictors std. Beta std 95% CI p 
NAWM tNAA/tCr 0.19 0.01 – 0.36 0.04 
Paced auditory serial addition task (n = 119) 
Predictors std. Beta std 95% CI p 
NAWM tNAA 0.17 0.01 – 0.34 0.04 
Gender* -0.23 -0.42 to -0.05 0.01 
T2 lesion volume -0.47 -0.64 to -0.30 <0.001 
Paced auditory serial addition task (n = 118)** 
Predictors std. Beta std 95% CI p 
NAWM tNAA/tCr 0.19 0.03 – 0.35 0.02 
Gender* -0.26 -0.44 to -0.08 0.006 
T2 lesion volume -0.46 -0.63 to -0.29 <0.001 
Paced auditory serial addition task (n = 119) 
Predictors std. Beta std 95% CI p 
NAWM mIns/tCr -0.22 -0.39 to -0.06 0.007 
Gender* -0.25 -0.43 to -0.07 0.008 
T2 lesion volume -0.47 -0.64 to -0.30 <0.001 
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 Paced Auditory Serial Addition Task (n = 119) 
Predictors std. Beta std 95% CI p 
GM tCho -0.17 -0.33 – -0.01 0.04 
T2 lesion volume -0.48 -0.65 – -0.31 <0.001 
 
*Male is reference category. ** 118 participants in this cohort as 1 case removed due to a highly leveraged point 
***Nine-hole peg test calculated by taking the reciprocal of the average of two trials for each arm and taking the 
mean 
CI = confidence interval, GM = grey matter, mIns = myoinositol, NAWM = normal appearing white matter, SE 
= standard error, std = standardised, tCho = glycerophosphocholine and phosphocholine, tCr = creatine and 
phosphocreatine, tNAA = N-acetyl aspartate and N-acetyl aspartyl glutamate.  
Covariates in model include: age, gender, duration from onset, occurrence of relapse in 2 years preceding 
randomisation, T2 lesion volume and normalised brain volume. Table highlights only the predictor variables that 




Figure 1. Proton magnetic resonance spectroscopy slice placement and mask 
The top panel demonstrates slice placement in the sagittal, coronal and axial planes. The 
lower panel shows an example of the chemical shift mask for normal appearing white matter 
and grey matter.  
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Figure 2. Example spectra and chemical shift grid  
 
Figure 2 shows A) Position where representative spectra come from including a lesion, B) 
accepted spectra in red and lesion in black, C) spectra from rejected voxel, position shown in 





Figure 3. Associations between neurometabolites and clinical disability measures 
9HPT = nine-hole peg test, IU = Institutional units, mIns = myoinositol, NAWM = normal 
appearing white matter, PASAT3 = Paced auditory serial addition task, tCr = creatine and 
phosphocreatine, tNAA = N-acetyl aspartate and N-acetyl aspartyl glutamate  
 
The scatterplots with the line of best fit and 95% confidence intervals are shown for the 
associations in normal appearing white matter between A. tNAA/tCr and nine-hole peg test 
[Rho=0.23, 95% CI [0.06-0.40], B. tNAA and Paced auditory serial addition task, [Rho=0.21, 
95% CI [0.03-0.38] C. tNAA/tCr and Paced auditory serial addition task [Rho=0.19, 95% CI 
[0.01-0.36] D. mIns/tCr and Paced auditory serial addition task [Rho=-0.23, 95% CI [-0.39 to 
-0.05] and in grey matter between E. tCho and Paced auditory serial addition task [Rho=-
0.24, 95% CI [-0.40 to -0.06]. 
